Equillium Q2 post narrower net loss than expected; starts R&D initiatives

Equillium

13/08/2026 21:20

Overview
US biotech innovator's Q2 net loss narrowed and beat analyst expectations
Q2 loss per share beat analyst expectations
Company expects cash position to fund operations into 2029

Outlook
Equillium expects to start Phase 1 EQ504 study in Q4 2026, with data about six months later
Company expects cash and cash equivalents to fund operations into 2029
Equillium is advancing IND-enabling activities for EQ504 as an inhaled therapy and EQ302 for celiac disease

Result Drivers
PIPELINE PROGRESS - Co cited continued advancement of EQ504 toward clinical trials, including manufacturing completion and planned regulatory submissions
R&D INITIATIVES - Co initiated IND-enabling development for EQ504 as an inhaled therapy and for EQ302 for celiac disease

Company press release: ID:nGNX9FNwHp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.04
$0.05 (9 Analysts)
Q2 Net Loss
Beat
$4.69 mln
$5.91 mln (10 Analysts)
Q2 Operating Income
Beat
-$5.16 mln
-$6.14 mln (10 Analysts)
Q2 Loss Per Basic Share
 
$0.04
 
Q2 Operating Expenses
 
$5.16 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Equillium Inc is $7.00, about 221.1% above its August 12 closing price of $2.18

Reuters Recommended Reads
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 13 - Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Aug 13 - Artelo Biosciences Q2 net loss narrows as R&D expenses fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)